Profiling analysis of circulating microRNA expression in cervical cancer

YUZO NAGAMITSU, HIROTAKA NISHI, TORU SASAKI, YOTARO TAKAESU, FUMITOSHI TERAUCHI and KEIICHI ISAKA

Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo 160-0023, Japan

Received December 18, 2015; Accepted April 18, 2016

DOI: 10.3892/mco.2016.875

Abstract. MicroRNA (miRNA) expression is altered in cancer cells and is associated with the development and progression of various types of cancer. Accordingly, miRNAs may serve as diagnostic or prognostic biomarkers in cancer patients. In this study, we attempted to analyze circulating exosomal miRNA in patients with cervical cancer. Total RNA was extracted from the serum of healthy subjects, subjects with cervical intraepithelial neoplasia (CIN) and patients with cervical cancer. We first investigated miRNA expression profiles in 6 serum samples from healthy subjects and patients with cervical cancer using the miRCURY LNA microRNA array. miRNAs with significant differences in expression were validated in a larger sample set by quantitative reverse transcription-polymerase chain reaction, using TaqMan gene expression assays. The results of the miRCURY LNA microRNA array indicated that 6 of 1,223 miRNAs found in serum samples from cervical cancer patients and normal controls exhibited a >3.0-fold change in expression level in subjects with cervical cancer, with a P-value of <0.01. In a validation set (n=131) that investigated the expression of 4 of the 6 miRNAs (miR-483-5p, miR-1246, miR-1275 and miR-1290), miR-1290 was found to have significantly higher expression levels in cervical cancer samples (n=45) compared with control samples (n=31). We also found that the median levels of these miRNAs were significantly higher in subjects with cervical cancer (n=45) compared with those in subjects with CIN (n=55). Circulating miRNAs were not correlated with clinicopathological parameters. However, receiver operating characteristic curve analysis suggested that these serum miRNAs may be useful diagnostic markers in cervical cancer. The expression of circulating miR-1290 was significantly higher in the blood of cervical cancer patients compared with that in controls and may thus serve as a useful biomarker in cervical cancer diagnosis. However, larger studies are required to fully elucidate the role of circulating exosomal miRNAs in cervical cancer.

Introduction

Cervical cancer is the second most common cancer in women worldwide after breast cancer, and it is particularly prevalent in developing countries (1), accounting for ~275,100 deaths annually worldwide (2). Cervical cancer is caused by persistent infection by high-risk types of the human papillomavirus (HPV) (3). Histologically, cervical cancer is almost entirely classified into two types: Squamous cell carcinoma (SCC; ~80%) and adenocarcinoma (~5-20%) (4). SCC develops from cervical intraepithelial neoplasia (CIN), whereas adenocarcinoma develops from intraepithelial adenocarcinoma and glandular dysplasia. To reflect their relative risk of progression to cervical cancer, CIN1 is considered low-grade CIN, whereas CIN2-3 is considered high-grade CIN. High-grade CIN may arise 2-3 years after high-risk HPV infection, subsequently causing cervical cancer after ≥10 years (5).

The most widely known tumor marker for cervical cancer is SCC antigen, which is a tumor-associated antigen identified by Kato et al in 1977 (6). The positive detection rate of SCC antigen in each clinical stage of cervical cancer is 2.4% (stage 0), 22.2% (stage I), 56.7% (stage II), 76.4% (stage III), 76.9% (stage IV) and 87% in recurrent cancer (7). However, the positive detection rate is low in early stages.

MicroRNAs (miRNAs) are small (typically 19-25 nucleotides), non-coding, endogenous, single-stranded RNAs. miRNAs were first described in 1993 by Lee et al in Caenorhabditis elegans (8). The majority of miRNAs negatively regulate target mRNAs in diverse biological processes, including cell proliferation, differentiation, development, metabolism and death. miRNAs are often aberrantly expressed in a number of human malignancies, and play key roles in tumor initiation and development. miRNAs suppress the translation of target mRNAs, mainly by binding to their 3'-untranslated region (9). Moreover, miRNAs significantly affect the expression of tumor oncogenes and suppressor genes, being involved in both tumor promotion and tumor suppression. Furthermore, epigenetic changes, such as DNA methylation, are involved in the abnormal expression of certain miRNAs (10). A single miRNA may have thousands of targets and approximately one-third of human genes may be controlled by miRNAs (11).

Correspondence to: Dr Hirotaka Nishi, Department of Obstetrics and Gynecology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
E-mail: nishih@tokyo-med.ac.jp

Key words: biomarker, microRNA, cervical cancer, miR-1290
The mechanism of miRNA expression in cancer cells has not been fully elucidated. However, altered expression of miRNAs has been detected in various types of cancer and appears to play a major role in the onset and progression of cancer.

It was recently discovered that miRNAs embedded in the small granules of exosomes are secreted into extracellular regions, including serum, urine and saliva (12). Serum miRNA detection may serve as a diagnostic or prognostic biomarker in cancer patients. Accordingly, our study was designed to analyze circulating miRNA levels in subjects with cervical cancer, in order to assess the potential value of miRNAs as diagnostic biomarkers.

Materials and methods

Study design and study population. A total of 131 subjects participated in the study, which was conducted at the Tokyo Medical University Hospital from April, 2010 to March, 2012. Of these subjects, 45 had cervical cancer, 55 had CIN and 31 were healthy. The research protocol was approved by our Institutional Review Board (approval no. 3268) and informed consent was obtained from all the subjects. Of the 45 patients with cervical cancer, 7 were stage Ia, 16 were stage Ib, 10 were stage IIb, 3 were stage III and 2 were stage IV. Of the 55 subjects with CIN, 15 were CIN1, 16 were CIN2 and 24 were CIN3. The patient backgrounds were obtained through interviews. Blood samples were collected prior to chemotherapy and radiation therapy. Cervical cancer and CIN were diagnosed on the basis of histological examinations. The characteristics of the subjects are summarized in Table I.

The present study was conducted in three phases (Fig. 1). In the first phase (screening phase), we performed comprehensive analysis of the serum miRNA of the cervical cancer subjects using a microarray, and selected 6 candidate miRNAs. We used 10 samples in total, 5 from cervical cancer subjects and 5 from healthy subjects. In the second phase (selection phase), the 6 candidate miRNAs were narrowed down to 4 using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). For the RT-qPCR, we used serum miRNA from 20 subjects with cervical cancer and 10 healthy subjects. In the third phase (validation phase), we performed RT-qPCR on the 4 miRNAs identified during the selection phase. In order to validate these 4 miRNAs, we examined the serum miRNA of 45 subjects with cervical cancer, 55 subjects with CIN and 31 healthy subjects, performed statistical processing and investigated the potential of each miRNA as a tumor marker.

Identification of 4 miRNA species by qPCR. In the selection phase, total RNA was extracted from the serum of 20 subjects with cervical cancer and 10 healthy subjects. RT-qPCR was performed on the total RNA, and 4 miRNA species were selected (miR-483-5p, miR-1246, miR-1275 and miR-1290) from the 6 miRNA species. In the validation phase, multiple samples were used to validate the miRNAs. Total RNA was extracted from the serum of 45 subjects with cervical cancer, 55 subjects with CIN and 31 healthy subjects, and subjected to RT-qPCR.

Serum preparation and total RNA extraction. Venous blood samples were collected from cervical cancer patients and healthy controls. The samples were separated into blood cells and serum by centrifugation, and stored at -5˚C. Total RNA in the serum was isolated using ISOGEN-LS, according to the manufacturer’s instructions. Briefly, 250 µl of serum was homogenized in 750 µl of ISOGEN-LS and 200 µl of chloroform was added to the sample, which was centrifuged. Following additional chloroform extraction and precipitation with isopropanol, the RNA sample was suspended in 20 µl of nuclease-free water (13).

Validation of miRNA expression by qPCR. We quantified miRNAs using TaqMan MicroRNA assays (Applied Biosystems, Foster City, CA, USA) with modifications and miRNA-specific stem-loop primers (has-miR-1290; Applied Biosystems). First, each miRNA was specifically reverse-transcribed to cDNA according to the manufacturer’s protocol, using TaqMan miRNA RT-Kit with stem-loop RT-primer and the Applied Biosystems 9800 Fast Thermal Cycler. Second, qPCR was performed for each specific miRNA using an RT-primer with Universal Master Mix on the Applied Biosystems StepOnePlus™ Real-Time PCR system (Life Technologies Corporation, Carlsbad, CA, USA). Sequence detection was performed according to the manufacturer’s protocol. The reaction mixtures were incubated at 95˚C for 2 min, followed by 50 cycles at 95˚C for 15 sec and 60˚C for 1 min. Each sample was analyzed in duplicate. The cycle thresholds (Ct) for subjects with cervical cancer, subjects with CIN and healthy subjects were calculated and normalized to miR-16, which was found in the literature to be the most widely-used endogenous control miRNA for RT-qPCR (14). The expression levels of miRNAs in subjects with cervical cancer and those with CIN relative to healthy controls were calculated using the comparative Ct method. The average Ct value of the control miR-16 for every sample was subtracted from the Ct value for each respective mature miRNA reaction, resulting in the ΔCt value. The -ΔΔCt value was calculated by subtracting the -ΔCt value of a normal sample from the respective -ΔCt values of the patient samples. Expression of miR-1290 was normalized using the 2^-ΔΔCt method (13,14). The miR-1290 expression profile was used to create a receiver operating characteristic (ROC) curve, which is a graphical plot of the true-positive vs. the false-positive rate. The area under the ROC curve represents the discrimination accuracy.

Statistical analysis. Statistical analysis of the causal association between the clinical background and expression level of the miRNAs was performed using EZR software (15).
P-value of <0.05 was considered to indicate statistically significant differences.

Results

miRNA expression status in cervical cancer. The characteristics of the 131 subjects are summarized in Table I. The samples used in this study were obtained from subjects with CIN, subjects with cervical cancer undergoing surgery or biopsy and healthy volunteers, following informed consent. Table I shows the characteristics of the patients with cervical cancer. Total RNA was extracted from the serum. We first investigated the miRNA expression profiles using miRCURY LNA microRNA array (Exiqon, Copenhagen, Denmark) in serum samples from 6 patients with cervical cancer and 6 healthy subjects to screen for candidate miRNAs associated with the development or progression of cervical cancer. The purpose of this analysis was to screen for a specific miRNA which may serve as a diagnostic or prognostic biomarker for cervical cancer patients. Initially, we compared miRNA expression in the serum of cervical cancer patients to that in the serum of healthy controls. Of the 1,223 miRNAs compared in serum samples from cervical cancer patients and healthy controls using a miRCURY LNA microRNA array, 6 were found to exhibit a >3.0-fold change in their expression level (P<0.01).

To perform a technical selection of the array results, we analyzed 6 miRNAs in the serum of 20 patients with cervical cancer and 10 healthy subjects by RT-qPCR using TaqMan gene expression assays (Applied Biosystems). Among the 6 miRNAs examined, miR-485-5p, miR-1246, miR-1275 and particularly miR-1290, were found by RT-qPCR to be expressed at significantly higher levels in cervical cancer patients compared with healthy controls. As the difference in expression was particularly high for miR-1290, we focused on this miRNA in the next step.

Elevated miR-1290 in the serum of cervical cancer patients. We next determined whether miR-1290 could be detected in the serum and if it was more abundant in subjects with CIN and cervical cancer. We measured the miR-1290 concentration in 100 subjects with cervical neoplasia and 31 healthy controls. The expression level of miR-1290 was significantly elevated in the serum samples from subjects with cervical cancer, but not in those from subjects with CIN, compared with healthy controls (P<0.001 and P>0.05, respectively, t-test;
miR-1290 was used as a reference). The comprehensive analysis of the serum was performed using the multi-analyte serum miR-1290, which was significantly higher in subjects with cervical cancer compared with healthy subjects. The expression level of serum miR-1290 was the lowest in healthy subjects, higher in CIN subjects, and the highest in cervical cancer patients. The median serum miRNA-1290 expression level was 0.78 in healthy subjects, 2.46 in CIN subjects and 4.04 in cervical cancer patients (P<0.01, Kruskal Wallis test).

The ROC curve indicated that the serum levels of miR-1290 may differentiate subjects with cervical cancer from healthy controls, with ROC curve areas of 0.7957 (95% confidence interval: 0.6937-0.8977) (Fig. 3). With the cut-off at 3.959 (relative expression value), miR-1290 had a 90.3% sensitivity for cervical cancer and a specificity of 62.2%, compared with healthy controls.

Serum miR-1290 in subjects at each stage of cervical cancer. The median expression level of serum miR-1290 increased along with the stage of cervical cancer. The level in each group was as follows: Healthy group, 0.78; CIN1-2 group, 1.81; CIN3 group, 2.74; cervical cancer stage I group, 4.00; stage II group, 5.66; and stage III-IV group, 5.59 (P<0.01, Kruskal-Wallis test, Fig. 4). There was no significant difference by histological type, i.e., SCC and adenocarcinoma (Welch’s t-test, Fig. 5). In addition, there was no correlation between clinical data, such as smoking, SCC antigen level, carcinoembryonic antigen level and lymph node metastasis, and miRNA expression (Mann-Whitney U test).

Discussion

As some biomarkers are able to detect cancer at early stages, they may improve patient survival; thus, they are key to the prognosis and diagnosis of cancer. SCC antigen is a tumor marker in cervical cancer, but the level of this marker is not increased during the early stages. Several clinicians have long stressed the need for novel biomarkers for early detection of cervical cancer. Abnormal expression of miRNAs
has been reported in a number of cervical cancer tissues and cell lines (16). These miRNAs are able to promote cell proliferation and reduce apoptosis, affect cell invasion, and eventually contribute to the initiation and progression of cervical cancer (1). miRNAs are very stable and permit easy detection of specific types of cancer (17).

The identification of circulating miRNAs is one of the major scientific breakthroughs in recent years and it has revolutionized cell biology and medical science. Growth factors, such as cytokines, are the principal communication tools between cells, but communication by exosomes between the peripheral cells and cancer cells has also been noted to be significant (18). Circulating miRNAs function as ‘extracellular communication RNAs’ that play an important role in cell proliferation and differentiation (12). Blood-based miRNA profiling is not as reliable as tissue-based miRNA-profiling, but offers the potential for early, non-invasive, sensitive and specific cervical cancer detection and screening. Recently, several circulating miRNAs have been identified as potential serum biomarkers in different cancer types (19). These serum miRNAs may be effective as predictive biomarkers in cancer. Chen et al revealed that serum miRNA expression level is correlated with specific types of cancer, such as lung and colorectal cancer (17). Serum miRNAs are non-invasive biomarkers that may permit early detection of cancer.

We investigated the expression of serum miRNAs in healthy subjects, subjects with CIN and patients with cervical cancer using an miRNA microarray and RT-qPCR. The expression of serum miR-1290 was the lowest in healthy subjects, higher in CIN subjects, and the highest in cervical cancer patients. Moreover, the expression level of serum miR-1290 was higher in high-grade CIN subjects compared with that in subjects with lower-grade CIN. The expression level of miR-1290 tended to increase with advancing clinical stage of cervical cancer. High-risk HPV infection plays a central role in cervical carcinogenesis. These high-risk HPV serotypes are found in CIN, even in CINI. HPV infection may increase miR-1290 expression directly or indirectly, since miR-1290 is already increased in CINI. In order to normalize the miRNA expression level, miR-16 was used as an internal control, as previously reported (13,14,20).

The miR-1290 gene is present in chromosome 1:19,223,565-19,223,642 (http://www.mirbase.org/). Some of the functions of miR-1290 have been previously reported. Wu et al suggested that miR-1290 is significantly upregulated in colon cancer tissues (21); moreover, they found that upregulation of miR-1290 impairs cytokinesis and leads to the formation of multinucleated cells in vitro and in vivo, while also resulting in Akt and nuclear factor-kB activation, which maintains cell proliferation (21). Endo et al suggested that miR-1290 and its potential target genes, forkhead box protein A1 (FOXA1) and N-acetyltransferase (NAT) 1, may be associated with the characteristics of estrogen receptor-positive breast cancer (22). FOXA1 is a forkhead family transcription factor, and arylamine NATs, known as drug- and carcinogen-metabolizing enzymes, transfer an acetyl group from acetyl coenzyme A to arylamines. They also suggested that B-cell lymphoma 2 (BCL2) and microtubule-associated protein tau (MAPT) are potential targets of miR-1290 according to in silico analysis. BCL2 is an anti-apoptotic protein that exerts an antiproliferative effect through affecting cell cycle entry. MAPT binds to both the outer and the inner surfaces of microtubules, leading to tubulin assembly and microtubule stabilization (22). It has been reported that 6 miRNAs, including miR-1290, are upregulated in drug-sensitive cells following Y-Box protein 1 inhibition, but no differences in miRNA expression have been detected in multidrug-resistant gastric carcinoma cells (23). It has also been reported that 36 miRNAs, including miR-1290, circulate at higher levels in subjects with renal cell carcinoma compared with those in healthy controls (24).

We found that serum circulating miR-485-5p, miR-1246 and miR-1275, as well as miR-1290, were significantly higher in cervical cancer subjects compared with healthy controls. The expression of miR-485-5p and miR-1275 was significantly downregulated in hepatocellular carcinoma (HCC) tissues (25,26). In particular, miR-485-5p expression was inversely correlated with TNM stage and metastasis in HCC samples (25). Serum miR-1246 was significantly higher in primary colorectal and esophageal cancer patients compared with in healthy controls and significantly correlated with TNM stage (27,28). Therefore, these three miRNAs (miR-485-5p, miR-1246 and miR-1275), may be biomarkers for cervical cancer with lower specificity.

In conclusion, serum miR-1290 appears to be a useful biomarker for the early detection of cervical cancer. It may reduce the need for invasive cervical biopsies and be useful in predicting the prognosis of cervical cancer. Larger studies are required to fully elucidate the role of miR-1290 in cervical cancer, and to determine whether serum miR-1290 may serve as a diagnostic marker or biomarker of treatment efficacy in this disease.

Acknowledgements

The authors would like to thank Ms. Chinatsu Yoneyama (Department of Obstetrics and Gynecology, Tokyo Medical University) and Dr Tomohiro Umezu (Department of Molecular Oncology, Institute of Medical Science, Tokyo Medical University) for providing invaluable experimental assistance. This study was supported by the Private University Strategic Research Based Support Project (grant no.,S1311016) and Grants-in-Aids (grant no.,24592533) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References


9. Lytle JR, Yario TA and Steitz JA: Target miRNAs are repressed as efficiently by microRNA-binding sites in the 5'UTR as in the 3'UTR. Proc Natl Acad Sci USA 104: 9667-9672, 2007.


